New Delhi [India] ): Bharat Biotech’s US partner Ocugen has announced that it had asked the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of Covaxin for children below 18.
“We are pleased to announce our EUA filing to the US-Food and Drug Administration (FDA) through our partners- Ocugen,” tweeted Dr Raches Ella, Bharat Biotech’s clinical lead for Covid-19 vaccines. The World Health Organisation (WHO) on Wednesday granted approval for Emergency Use Listing (EUL) for Bharat Biotech’s COVID-19 vaccine, Covaxin.
The approval was done on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL), an independent advisory panel that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.
Bharat Biotech’s Covaxin and AstraZeneca and Serum Institute’s Covishield are the two widely used vaccines in India.
Must Read
- Covaxin gets emergency approval for children aged 2-18 years
- Bharat Biotech gets SEC approval for phase 3 clinical trials…
- Bharat Biotech concludes phase 3 Covaxin trial, claims 77.8%…
- Bharat Biotech awaits feedback from WHO for COVID-19 vaccine…
- WHO to decide on Bharat Biotech's Covaxin emergency usage in…
- Guyana adds Bharat Biotech's Covaxin to list of recognised…
- Bharat Biotech's Covaxin phase 3 data shows 77.8 pc efficacy…
- Covaxin found to be safe, immunogenic in 2-18 age group in…
- Covaxin-maker Bharat Biotech MD D Krishna Ella and Suchitra…
- Validation awaited to Covaxin for children aged between 2-18…